Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Entecavir 0.5 mg
The First People's Hospital of Lianyungang
Hepatitis B
1 trial -
Enteral immunonutrition
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Locally Advanced Nasopharyngeal Carcinoma
1 trial -
Escitalopram
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Major Depressive Disorder (MDD)
1 trial -
Escitalopram (Oral antidepressant)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Depression - Major Depressive Disorder
1 trial -
Escitalopram Oxalate Tablets
The First People's Hospital of Lianyungang
Major Depressive Disorder
1 trial -
Esketamine
The First People's Hospital of Lianyungang
Postoperative Cognitive Dysfunction
1 trial -
Esketamine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Anesthesia
1 trial -
Esketamine
The First People's Hospital of Lianyungang
Post Induction Hypotension
1 trial -
Esketamine at low dose
The First People's Hospital of Lianyungang
Insomnia
1 trial -
Esketamine, Sulfentanil or/and Remifentanil
Second Affiliated Hospital of Soochow University
Opioid Analgesic Adverse Reaction
1 trial -
Esketamine-lidocaine group
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Postoperative Chronic Pain
1 trial -
Etomidate
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Postoperative Complications
1 trial -
Evaluation of social, cultural and behavioral factors
International Peace Maternity and Child Health Hospital
Cardio-vascular Disease
1 trial -
Exclusive Enteral Nutrition Therapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Crohn's Disease
1 trial -
Experimental group
The First People's Hospital of Lianyungang
Overweight or Obesity
1 trial -
External beam radiotherapy
International Peace Maternity and Child Health Hospital
Squamous Cell Carcinoma of the Head and Neck
1 trial -
FAST Technique
Xiyuan Hospital of China Academy of Chinese Medical Sciences
ST-Segment Elevation Myocardial Infarction
1 trial -
FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Biliary Tract Neoplasms
1 trial -
Favipiravir
The First People's Hospital of Lianyungang
COVID-19
1 trial -
Febuxostat
The First People's Hospital of Lianyungang
Refractory Gout
1 trial -
Fecal Microbiota Transplantation (FMT)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Type 1 Diabetes
1 trial -
Fei Re Qing Granules
The First People's Hospital of Lianyungang
Severe Pneumonia Caused by Multidrug-resistant Gram-negative Bacterial Infection
1 trial -
Ferrous Fumarate Oral Tablet
Hospital Authority, Hong Kong
Iron Deficiency Anemia Treatment
1 trial -
Fluorometholone
Hospital Authority, Hong Kong
Pterygium of the Conjunctiva and Cornea
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources